A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
- on behalf of the Taiwan Cooperative Oncology Group
研究成果: Article › 同行評審
151
連結會在新分頁中打開
引文
斯高帕斯（Scopus）